Xeltis Releases 12-Month EU Pivotal Data for aXess™ in Hemodialysis Treatment

Xeltis announced groundbreaking 12-month clinical data from the aXess multi-center EU pivotal trial, demonstrating improved secondary patency and lower intervention rates for aXess™ compared to conventional options in hemodialysis treatment. The trial involved 120 patients and showed 79% secondary patency and a low infection rate of 3%. The results highlight aXess™’s potential in transforming vascular access options for patients.